SCHEMBL2258978

SCHEMBL2258978

COCCN1CCN(C(=O)c2cc(C(F)(F)F)nn2-c2ccccc2Cl)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 4/20 0.44
▸ DRD3 P35462 3/20 0.44
▸ RORC P51449 1/20 0.43
▸ KCNA5 P22460 3/20 0.43
▸ NAMPT P43490 1/20 0.41
▸ CNR1 P21554 1/20 0.41
▸ CNR2 P34972 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ RXRA P19793 2/20 0.39
▸ NR1H2 P55055 2/20 0.39
▸ NR1H3 Q13133 2/20 0.39
▸ PKM P14618 1/20 0.39
▸ ADORA2B P29275 1/20 0.39
▸ HTR4 Q13639 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260490 0.88 DRD2 (0.44) DRD2DRD3CNR1CNR2RXRA
SCHEMBL2255840 0.87 DRD2 (0.44) DRD2DRD3CNR1CNR2RXRA
SCHEMBL2257006 0.84 KCNA5 (0.42) DRD2DRD3KCNA5HTR2A
SCHEMBL2256006 0.83 CNR1 (0.58) CNR1CNR2CYP1A2CYP2D6CYP2C19
SCHEMBL2259510 0.83 RXRA (0.42) DRD2DRD3RXRANR1H2NR1H3
SCHEMBL2257730 0.83 THRB (0.59) DRD2DRD3HTR2A
SCHEMBL2257175 0.82 KMT2A (0.52) CNR1CNR2RXRANR1H2NR1H3
SCHEMBL2258635 0.82 ALDH1A1 (0.47) CYP1A2CYP3A4CYP2C19
SCHEMBL2260917 0.82 IRAK4 (0.44) DRD2DRD3NPC1RAB9AKMT2A
SCHEMBL2261296 0.82 RXRA (0.46) CNR1CNR2RXRANR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121621-B1 LXR AND FXR MODULATORS EXELIXIS PATENT CO LLC (US) 2014-05-07 — — EP disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed
WO-2008073825-A1 LXR AND FXR MODULATORS EXELIXIS, INC. (US) 2008-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069367-A1 LXR and FXR Modulators NR1H3, NR1H2, NR1H4 DRD2 1486/4885DRD3 1389/4885RORC 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback